Profile

Esperion Therapeutics, Inc. is a public American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan. Pfizer acquired the original Esperion in 2004 for US$1,300,000,000 as a defensive move to prevent ETC-216 from falling into competitors' hands. Two years later, in 2006, Pfizer decided to kill the Esperion organization and development of ETC-216. In May 2008, Dr. Roger Newton, Esperion's founder and chief scientific officer, raised sufficient capital to acquire rights to ETC-1002 and Esperion from Pfizer, thereby leading to a second independent period for the company. In June 2013, Esperion became a public company again through an initial public offering. As of April 2014, Esperion was traded on NASDAQ under the symbol "ESPR".